SCHEMBL17023244

SCHEMBL17023244

CS(=O)(=O)NCCOC(=O)/C=C/C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 13/20 0.55
ATM Q13315 1/20 0.40
ALDH1A1 P00352 3/20 0.37
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
RAB9A P51151 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ALOX15 P16050 1/20 0.34
RECQL P46063 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MEN1 O00255 1/20 0.34
HTT P42858 1/20 0.34
KMT2A Q03164 1/20 0.34
KEAP1 Q14145 1/20 0.31
NFE2L2 Q16236 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17023245 1.00 HCAR2 (0.55) HCAR2ATMALDH1A1MAPTKDM4E
SCHEMBL17023243 0.93 ATM (0.45) HCAR2ATMALDH1A1MAPTRAB9A
SCHEMBL17036710 0.88 HCAR2 (0.46) HCAR2ATMALDH1A1MAPTKDM4E
SCHEMBL18395418 0.86 HCAR2 (0.48) HCAR2ATMALDH1A1MAPTRAB9A
SCHEMBL18405663 0.86 HCAR2 (0.48) HCAR2ATMALDH1A1MAPTRAB9A
SCHEMBL18406944 0.82 ATM (0.52) HCAR2ATMALDH1A1MAPTRAB9A
SCHEMBL18395083 0.82 HCAR2 (0.44) HCAR2ATMALDH1A1MAPTKDM4E
SCHEMBL18405667 0.82 HCAR2 (0.44) HCAR2ATMALDH1A1MAPTKDM4E
SCHEMBL8685898 0.79 TSHR (0.48) ATMALDH1A1MAPTHSD17B10MEN1
SCHEMBL22912842 0.78 HCAR2 (0.62) HCAR2ATMALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3110793-B1 SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES ALKERMES PHARMA IRELAND LTD (IE) 2019-08-21 EP disclosed
US-10301256-B2 Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases ALKERMES PHARMA IRELAND LIMITED (IE) 2019-05-28 US disclosed
US-20170129851-A1 SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2017-05-11 US disclosed
US-9604922-B2 Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases ALKERMES PHARMA IRELAND LIMITED (IE) 2017-03-28 US disclosed
EP-3110793-A1 SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES Alkermes Pharma Ireland Limited (IE) 2017-01-04 EP disclosed
US-20150239829-A1 SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2015-08-27 US disclosed
WO-2015127450-A1 SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES ALKERMES PHARMA IRELAND LIMITED (IE) 2015-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10301256-B2 Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases SULT2A1, FH, STS HCAR2 544/4885ATM 3573/4885ALDH1A1 1312/4885
US-20170129851-A1 SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES SULT2A1, FH, STS HCAR2 544/4885ATM 3573/4885ALDH1A1 1312/4885
US-20150239829-A1 SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES SULT2A1, FH, STS HCAR2 544/4885ATM 3573/4885ALDH1A1 1312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.